Related Experiment Video
Updated: Dec 18, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Staphylococcus aureus Pneumonia in the Community
Hangyong He1, Richard G Wunderink2
1Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Abstract:
Staphylococcus aureus is an emergent etiology of community-acquired pneumonia (CAP) over the past 2 decades, with severe community-acquired pneumonia (SCAP) caused by methicillin-resistant S. aureus (MRSA) leading to critical illness and death. S. aureus colonization is associated with a high incidence of pneumonia. Panton-Valentine leukocidin (PVL) is one of the most important virulence factors of S. aureus associated with serious complications. In recent years, community-associated MRSA (CA-MRSA) clones that caused infections in young adults and healthy individuals with no exposure to health care settings and no classical risk factors have emerged. Clinical features at admission including concurrent influenza infection, hemoptysis, multilobar infiltrates, and neutropenia should suggest S. aureus CAP. Sputum Gram stains, cultures (or tracheobronchial aspirates or bronchoalveolar lavage in mechanically ventilated patients), polymerase chain reaction (nasopharyngeal or oropharyngeal or lower respiratory tract specimens), and two sets of blood cultures should be obtained from patients presenting with severe S. aureus CAP. For CAP due to methicillin-susceptible S. aureus, first-line therapy is usually cefazolin, oxacillin, or ceftaroline. For CA-MRSA pneumonia, linezolid is recommended. If vancomycin or teicoplanin are used, combination with clindamycin or rifampicin should be considered in cases of PVL-positive MRSA CAP.
Insights
Staphylococcus aureus is a growing cause of community-acquired pneumonia (CAP), especially severe cases from MRSA, leading to critical illness. Early recognition and appropriate antibiotic therapy are crucial for managing S. aureus CAP.
Area of Science:
- Infectious Diseases
- Pulmonology
- Microbiology
Background:
- Staphylococcus aureus is an increasing cause of community-acquired pneumonia (CAP), particularly severe forms (SCAP).
- Methicillin-resistant S. aureus (MRSA), especially community-associated strains (CA-MRSA), poses a significant threat, causing severe illness and death.
- Panton-Valentine leukocidin (PVL) is a key virulence factor in severe S. aureus infections.
Purpose of the Study:
- To highlight Staphylococcus aureus as an emergent cause of CAP.
- To discuss the clinical features, diagnostic methods, and treatment strategies for S. aureus CAP.
- To emphasize the challenges posed by CA-MRSA and PVL-positive strains.
Main Methods:
- Review of clinical features suggestive of S. aureus CAP, including influenza coinfection, hemoptysis, multilobar infiltrates, and neutropenia.
- Recommendations for diagnostic workup, including Gram stains, cultures, PCR, and blood cultures for severe cases.
- Outline of treatment guidelines for methicillin-susceptible S. aureus (MSSA) and MRSA CAP.
Main Results:
- S. aureus is a significant pathogen in CAP, with MRSA strains associated with higher mortality.
- PVL-producing CA-MRSA strains are emerging in healthy individuals.
- Specific clinical signs and diagnostic tests aid in early identification.
Conclusions:
- Prompt diagnosis and appropriate antimicrobial selection are critical for improving outcomes in S. aureus CAP.
- Cefazolin, oxacillin, or ceftaroline are recommended for MSSA CAP.
- Linezolid is the preferred agent for CA-MRSA pneumonia; combination therapy may be considered for PVL-positive MRSA CAP.
More Related Videos
08:25Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.